کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2540254 | 1559756 | 2016 | 15 صفحه PDF | دانلود رایگان |
• Different subsets of tissue-derived DCs have been identified in the skin, lung, liver, gut and kidney, etc.
• Malfunction of DCs contributes to human diseases such as autoimmunity, allergy, and cancer.
• Evidence of the potential effectiveness of DC therapy provides optimism for future investigation and development.
Dendritic cells (DCs) control immune responses and are central to the development of immune memory and tolerance. DCs initiate and orchestrate immune responses in a manner that depends on signals they receive from microbes and cellular environment. Although DCs consist mainly of bone marrow-derived and resident populations, a third tissue-derived population resides the spleen and lymph nodes (LNs), different subsets of tissue-derived DCs have been identified in the blood, spleen, lymph nodes, skin, lung, liver, gut and kidney to maintain the tolerance and control immune responses. Tissue-resident DCs express different receptors for microbe-associated molecular patterns (MAMPs) and damage-associated molecular patterns (DAMPs), which were activated to promote the production of pro- or anti-inflammatory cytokines. Malfunction of DCs contributes to diseases such as autoimmunity, allergy, and cancer. It is therefore important to update the knowledge about resident DC subsets and diseases associated with DC malfunction.
Journal: International Immunopharmacology - Volume 34, May 2016, Pages 1–15